066700 — THERAGEN ETEX CO Balance Sheet
0.000.00%
- KR₩123bn
- KR₩155bn
- KR₩222bn
- 65
- 80
- 13
- 53
Annual balance sheet for THERAGEN ETEX CO, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,069 | 15,832 | 13,602 | 21,421 | 23,280 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 75,813 | 59,691 | 58,779 | 62,298 | 67,409 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 110,095 | 96,337 | 96,954 | 106,962 | 115,390 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 47,187 | 42,461 | 40,695 | 41,422 | 41,653 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 241,498 | 534,886 | 350,073 | 246,553 | 243,135 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 72,261 | 65,240 | 74,693 | 74,839 | 85,721 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 105,637 | 160,764 | 127,377 | 102,955 | 107,434 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
ESOP Debt Guarantee | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 135,862 | 374,121 | 222,697 | 143,598 | 135,701 |
Total Liabilities & Shareholders' Equity | 241,498 | 534,886 | 350,073 | 246,553 | 243,135 |
Total Common Shares Outstanding |